Treatment Clinical Trials for Gallbladder Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are for gallbladder cancer treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-15 of 15
  • Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158 / KEYNOTE-158)

    In this study, participants with multiple types of advanced (unresectable and / or metastatic) solid tumors that have progressed on standard of care therapy will be treated with pembrolizumab.
    Location: 18 locations

  • Open-Label Study of PEGPH20 With CIS and GEM; PEGPH20 With Atezolizumab, CIS and GEM; and Compared With CIS and GEM Alone in HA-high Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

    The study was conducted to assess the safety and tolerability of (1) polyethylene glycol (PEG) PEGylated Recombinant Human Hyaluronidase (PEGPH20) in combination with cisplatin (CIS) and gemcitabine (GEM) (PEGCISGEM), and (2) PEGPH20 in combination with CIS, GEM, and atezolizumab (PEGCISGEMATEZO).
    Location: 8 locations

  • Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer

    This protocol for Varlitinib is developed for the treatment of Biliary Tract Cancer. Varlitinib (also known as ASLAN001) is a small-molecule, adenosine triphosphate competitive inhibitor of the tyrosine kinases - epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER)2, and HER4. Varlitinib may be beneficial to subjects with cancer by simultaneous inhibition of these receptors. The purpose of this study is to determine the safety and efficacy of Varlitinib in combination with capecitabine for the treatment of Biliary Tract Cancer. Treatment groups are Varlitinib+capecitabine and Placebo + capecitabine
    Location: 5 locations

  • Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer

    In the dose escalation phase (Part 1), this study will determine the dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD) and recommended Phase 2 (RPII) dose of NC 6004 in combination with gemcitabine. In the expansion phase of the study (Part 2), study will evaluate the activity, safety, and tolerability at the RPII dose identified in Part 1 in patients with squamous NSCLC, biliary tract, and bladder cancer.
    Location: 3 locations

  • GL-ONC1 with or without Eculizumab in Treating Patients with Solid Organ Cancers before Surgery

    This phase Ib trial studies the side effects and best dose of light-emitting oncolytic vaccinia virus GL-ONC1 (GL-ONC1) when given with or without eculizumab in treating patients with solid organ cancers before surgery. A virus called GL-ONC1, which has been changed in a certain way, may be able to kill tumor cells without damaging normal cells. Monoclonal antibodies, such as eculizumab, may interfere with the ability of tumor cells to grow and spread. Giving GL-ONC1 with or without eculizumab may work better in treating patients with solid organ cancers.
    Location: 2 locations

  • Tumor Infiltrating Lymphocytes, Aldesleukin, and Pembrolizumab after Chemotherapy in Treating Patients with Metastatic Cancers

    This phase II trial studies how well tumor infiltrating lymphocytes, aldesleukin, and pembrolizumab work after chemotherapy in treating patients with cancers that has spread to other parts of the body (metastatic). Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Aldesleukin may stimulate lymphocytes to kill tumor cells. Treating lymphocytes with aldesleukin in the laboratory may help the lymphocytes kill more tumor cells when they are put back in the body after chemotherapy.
    Location: 2 locations

  • TAS-102 in Treating Advanced Biliary Tract Cancers

    This phase II trial studies how well trifluridine / tipiracil hydrochloride combination agent TAS-102 (TAS-102) works in treating participants with biliary tract cancers that have spread to other places in the body. Drugs used in the chemotherapy, such as trifluridine / tipiracil hydrochloride combination agent TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: 2 locations

  • Pembrolizumab, Capecitabine, and Oxaliplatin in Treating Patients with Metastatic Biliary Tract Cancer That Cannot Be Removed by Surgery

    This phase II trial studies the side effects and how well pembrolizumab, capecitabine, and oxaliplatin work in treating patients with biliary tract cancer that has spread to other places in the body and cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab, capecitabine, and oxaliplatin may work better in treating patients with biliary tract cancer.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Nivolumab with Gemcitabine Hydrochloride and Cisplatin or Ipilimumab as First Line Therapy in Treating Patients with Advanced Biliary Tract Cancer That Cannot Be Removed by Surgery

    This randomized phase II trial studies how well nivolumab with gemcitabine hydrochloride and cisplatin or ipilimumab work as first line therapy in treating patients with biliary tract cancer that has spread to other places in the body, usually cannot be cured or controlled with treatment, and cannot be removed by surgery. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab with gemcitabine hydrochloride and cisplatin or ipilimumab may work better in treating patients with biliary tract cancer.
    Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

  • Durvalumab and Tremelimumab with and without Ablative Therapy in Treating Patients with Advanced Liver or Biliary Tract Cancer

    This pilot phase I / II trial studies how well durvalumab and tremelimumab with and without ablative therapy works in treating patients with liver or bile duct cancer that cannot be removed by surgery and has not responded to previous treatment. Monoclonal antibodies, such as durvalumab and tremelimumab, may block specific proteins found on white blood cells which may strengthen the immune system and control tumor growth. Ablative therapies, such as radiofrequency ablation or cryoablation, use either heat or extreme cold to kill tumor cells. Transarterial chemoembolization uses substances to block the blood flow to the tumor. Durvalumab and tremelimumab with and without ablative therapies may help to control tumor growth.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Copanlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients with Cholangiocarcinoma That Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery

    This phase II trial studies how well copanlisib, gemcitabine hydrochloride, and cisplatin work in treating patients with cholangiocarcinoma that has spread to other places in the body or cannot be removed by surgery. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving copanlisib, gemcitabine hydrochloride, and cisplatin may work better in treating patients with cholangiocarcinoma.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Ramucirumab in Treating Patients with Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery

    This phase II trial studies how well ramucirumab works in treating patients with previously treated biliary cancers that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or have spread to other places in the body (metastatic) and cannot be removed by surgery. Monoclonal antibodies, such as ramucirumab, may block tumor growth in different ways by targeting certain cells.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Recombinant EphB4-HSA Fusion Protein with Standard Chemotherapy Regimens in Treating Patients with Advanced or Metastatic Solid Tumors

    This pilot phase Ib trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein when given together with standard chemotherapy regimens in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or have spread to other places in the body (metastatic). Drugs used in chemotherapy, such as recombinant EphB4-HSA fusion protein, paclitaxel albumin-stabilized nanoparticle formulation, gemcitabine hydrochloride, docetaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether standard chemotherapy regimens are more effective with recombinant ephB4-HSA fusion protein in treating advanced or metastatic solid tumors.
    Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California

  • Guadecitabine and Durvalumab in Treating Patients with Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

    This phase Ib trial studies the side effects and best dose of guadecitabine and how well it works when given together with durvalumab in treating patients with liver, pancreatic, bile duct, or gallbladder cancer that has spread to other places in the body. Guadecitabine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as durvalumab, may block tumor growth in different ways by targeting certain cells. Giving guadecitabine and durvalumab may work better in treating patients with liver, pancreatic, bile duct, or gallbladder cancer.
    Location: 2 locations

  • Oncolytic HSV-1 rRp450 in Treating Patients with Primary Liver Cancer

    This phase I trial studies the side effects and best dose of oncolytic HSV-1 rRp450 in treating patients with primary liver cancer. A virus called herpes simplex virus (HSV)-1, which has been changed in a certain way, may be able to kill tumor cells without damaging normal cells.
    Location: See Clinical Trials.gov